These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 1369132)

  • 1. Cytokine expression by recombinant viruses--a new vaccine strategy.
    Ramshaw IA; Ruby J; Ramsay A
    Trends Biotechnol; 1992 Dec; 10(12):424-6. PubMed ID: 1369132
    [No Abstract]   [Full Text] [Related]  

  • 2. Vaccinia and other poxvirus expression vectors.
    Moss B
    Curr Opin Biotechnol; 1992 Oct; 3(5):518-22. PubMed ID: 1368937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel vaccinia vector derived from the host range restricted and highly attenuated MVA strain of vaccinia virus.
    Sutter G; Moss B
    Dev Biol Stand; 1995; 84():195-200. PubMed ID: 7796954
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara.
    Ober BT; Brühl P; Schmidt M; Wieser V; Gritschenberger W; Coulibaly S; Savidis-Dacho H; Gerencer M; Falkner FG
    J Virol; 2002 Aug; 76(15):7713-23. PubMed ID: 12097585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccinia virus: a suitable vehicle for recombinant vaccines?
    Kaplan C
    Arch Virol; 1989; 106(1-2):127-39. PubMed ID: 2669685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of an attenuated vaccinia virus strain, LC16m0, and its recombinant virus vaccines.
    Sugimoto M; Yamanouchi K
    Vaccine; 1994 Jun; 12(8):675-81. PubMed ID: 8091843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attenuation of a vaccine strain of vaccinia virus via inactivation of interferon viroceptor.
    Dénes B; Gridley DS; Fodor N; Takátsy Z; Timiryasova TM; Fodor I
    J Gene Med; 2006 Jul; 8(7):814-23. PubMed ID: 16634110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccinia virus: a tool for research and vaccine development.
    Moss B
    Science; 1991 Jun; 252(5013):1662-7. PubMed ID: 2047875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B5-deficient vaccinia virus as a vaccine vector for the expression of a foreign antigen in vaccinia immune animals.
    Viner KM; Girgis N; Kwak H; Isaacs SN
    Virology; 2007 May; 361(2):356-63. PubMed ID: 17188733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector.
    Ramírez JC; Gherardi MM; Rodríguez D; Esteban M
    J Virol; 2000 Aug; 74(16):7651-5. PubMed ID: 10906221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Replicating and host-restricted non-replicating vaccinia virus vectors for vaccine development.
    Moss B
    Dev Biol Stand; 1994; 82():55-63. PubMed ID: 7958483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attenuation and immunogenicity in primates of vaccinia virus recombinants expressing human interleukin-2.
    Flexner C; Moss B; London WT; Murphy BR
    Vaccine; 1990 Feb; 8(1):17-21. PubMed ID: 2316280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roles of vaccinia virus in the development of new vaccines.
    Moss B; Fuerst TR; Flexner C; Hugin A
    Vaccine; 1988 Apr; 6(2):161-3. PubMed ID: 3291453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of genes that modulate host immune responses in the immunogenicity and pathogenicity of vaccinia virus.
    Jackson SS; Ilyinskii P; Philippon V; Gritz L; Yafal AG; Zinnack K; Beaudry KR; Manson KH; Lifton MA; Kuroda MJ; Letvin NL; Mazzara GP; Panicali DL
    J Virol; 2005 May; 79(10):6554-9. PubMed ID: 15858042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safe and effective poxvirus vectors--NYVAC and ALVAC.
    Paoletti E; Tartaglia J; Taylor J
    Dev Biol Stand; 1994; 82():65-9. PubMed ID: 7958484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expression.
    Flexner C; Hügin A; Moss B
    Nature; 1987 Nov 19-25; 330(6145):259-62. PubMed ID: 3118219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative studies of a retrovirus versus a poxvirus vector in whole tumor-cell vaccines.
    Hodge JW; Schlom J
    Cancer Res; 1999 Oct; 59(20):5106-11. PubMed ID: 10537283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poxviruses as vaccine vectors.
    Pastoret PP; Vanderplasschen A
    Comp Immunol Microbiol Infect Dis; 2003 Oct; 26(5-6):343-55. PubMed ID: 12818621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of recombinant viruses to deliver cytokines influencing the course of experimental bacterial infection.
    Cheers C; Janas M; Ramsay A; Ramshaw I
    Immunol Cell Biol; 1999 Aug; 77(4):324-30. PubMed ID: 10457199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Target and non-target effects of a recombinant vaccinia-rabies virus developed for fox vaccination against rabies.
    Pastoret PP; Brochier B; Boulanger D
    Dev Biol Stand; 1995; 84():183-93. PubMed ID: 7796953
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.